Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. [electronic resource]
Producer: 20120521Description: 1948-59 p. digitalISSN:- 1097-0215
- Animals
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- CD8-Positive T-Lymphocytes -- drug effects
- Cancer Vaccines -- administration & dosage
- Carcinoembryonic Antigen -- genetics
- Cell Line, Tumor
- Colonic Neoplasms -- genetics
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Flow Cytometry
- Humans
- Immune System -- drug effects
- Indoles -- administration & dosage
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Neoplasms, Experimental -- drug therapy
- Pyrroles -- administration & dosage
- Receptors, Platelet-Derived Growth Factor -- immunology
- Signal Transduction -- drug effects
- Sunitinib
- T-Lymphocytes, Regulatory -- drug effects
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Intramural
There are no comments on this title.
Log in to your account to post a comment.